Generic Drug Development CDMO

Introduction Forced Degradation and Photostability Studies for Generic Drug ANDA Submissions form the analytical cornerstone required to demonstrate that a […]

Introduction Bioequivalence study design for complex generic drug products requires a comprehensive and integrated development strategy that combines precise qualitative/quantitative

Generic Drug Development CDMO Cross-Border Drug Development: One Testing Lab for Both FDA and Health Canada Submissions By Anusha Sinha

Peptide vs Small-Molecule CMC What Is the Difference Between a Peptide and a Small-Molecule Drug in Manufacturing? By Anusha Sinha

Peptide CDMO Strategy United States vs. Overseas Peptide CDMOs: Should You Reshore Your Supply Chain? By Anusha Sinha • August

Introduction A Biosimilar CDMO in United States plays a critical role in achieving analytical comparability and regulatory acceptance by applying

Introduction Partnering with a specialized biosimilar CDMO in Canada allows biopharmaceutical companies to address the complex technical, analytical, and regulatory

Introduction Biotechnology companies increasingly collaborate with a Peptide CDMO in United states to establish dependable domestic supply networks, address sophisticated

Introduction A Peptide CDMO in Canada offers the specialized synthetic chemistry expertise, cGMP-compliant manufacturing capabilities, and comprehensive orthogonal analytical testing